tetano
Editor, Senior Moderator
J Formos Med Assoc
. 2022 Aug 14;S0929-6646(22)00282-0.
doi: 10.1016/j.jfma.2022.07.009. Online ahead of print.
Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
Wang-Huei Sheng[SUP] 1 [/SUP], Chung-Cheng Wang[SUP] 2 [/SUP], Ching-Chi Chu[SUP] 3 [/SUP], Yueh-Juh Lin[SUP] 3 [/SUP], Sui-Yuan Chang[SUP] 4 [/SUP], Si-Man Ieong[SUP] 5 [/SUP], Shan-Chwen Chang[SUP] 6 [/SUP]
Affiliations
Abstract
We reported 25 recipients (14 females and 11 males) aged from 18 to 65 years who unexpectedly received a primary dose of undiluted BNT162b2 vaccine (180 μg). The most common adverse reactions included injection site pain (n = 22), followed by fever (9), fatigue (8), chest tightness (6), and dizziness (6). The most common laboratory abnormalities were anemia (n = 4) and elevated liver transaminase level (4), followed by abnormal leukocyte counts (3) and elevated D-dimer level (3). The adverse reactions and laboratory abnormalities of these recipients were mild and spontaneously recovered within a few weeks. Significant elevations of anti-SARS-CoV-2 spike IgG titers after a booster dose of the BNT162b2 were found. Similar to reports of BNT162b2 clinical trials, the adverse reactions and laboratory abnormalities of these recipients were mild, and they spontaneously recovered within a few weeks. These results provide clinical and immunological effects of undiluted BNT162b2 vaccine inoculation.
Keywords: Adverse events; Coronavirus disease 2019 (COVID-19); Immune response; Undiluted BNT162b2 vaccine.
. 2022 Aug 14;S0929-6646(22)00282-0.
doi: 10.1016/j.jfma.2022.07.009. Online ahead of print.
Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
Wang-Huei Sheng[SUP] 1 [/SUP], Chung-Cheng Wang[SUP] 2 [/SUP], Ching-Chi Chu[SUP] 3 [/SUP], Yueh-Juh Lin[SUP] 3 [/SUP], Sui-Yuan Chang[SUP] 4 [/SUP], Si-Man Ieong[SUP] 5 [/SUP], Shan-Chwen Chang[SUP] 6 [/SUP]
Affiliations
- PMID: 35977867
- DOI: 10.1016/j.jfma.2022.07.009
Abstract
We reported 25 recipients (14 females and 11 males) aged from 18 to 65 years who unexpectedly received a primary dose of undiluted BNT162b2 vaccine (180 μg). The most common adverse reactions included injection site pain (n = 22), followed by fever (9), fatigue (8), chest tightness (6), and dizziness (6). The most common laboratory abnormalities were anemia (n = 4) and elevated liver transaminase level (4), followed by abnormal leukocyte counts (3) and elevated D-dimer level (3). The adverse reactions and laboratory abnormalities of these recipients were mild and spontaneously recovered within a few weeks. Significant elevations of anti-SARS-CoV-2 spike IgG titers after a booster dose of the BNT162b2 were found. Similar to reports of BNT162b2 clinical trials, the adverse reactions and laboratory abnormalities of these recipients were mild, and they spontaneously recovered within a few weeks. These results provide clinical and immunological effects of undiluted BNT162b2 vaccine inoculation.
Keywords: Adverse events; Coronavirus disease 2019 (COVID-19); Immune response; Undiluted BNT162b2 vaccine.